Kunming Biomed International (KBI) announces the hiring of Kaiming Zhang as Head of Eye Diseases. "We welcome Kaiming joining us to strengthen KBI’s capability in metabolic complications such as diabetic retinopathy and establish eye disease technology platform in non-human primates (NHPs). This appointment demonstrates that KBI will continuously enhance the leading position in preclinical services in metabolic diseases and metabolic complications including heart failure, NASH/liver fibrosis, diabetic nephropathy and diabetic retinopathy". In addition, Kaiming’s leadership in this area will facilitate KBI’s quick expansion into other eye disease related to aging”, said Dr. Bob Zhang, CEO of KBI.

Kaiming Zhang is an expert in in vivo pharmacology of eye diseases. Prior to joining KBI, he spent more than 16 years in Allergan Pharmaceuticals in the US, responsible for various eye disease model development in non-human primates (NHPs) including diabetic retinopathy, glaucoma, age-related macular diseases, neuro degeneration, optic neuropathy, presbyopia, cornea disease etc. He has extensive experience in disease model characterization, structural and functional evaluations of the disease, trouble shooting, results analysis and interpretation. He has developed a visual psychophysics lab and achieved visual acuity and contrast sensitivity assessment in conscious animals. Mr. Zhang graduated from University of Science and Technology China majoring in Biology, and received his Computer Information training at Nashville State Tech in the US.